價(jià)格 | ¥530 | ¥1250 | ¥1860 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-02 |
中文名稱(chēng):氯西加酮 | 英文名稱(chēng):Losigamone |
CAS:112856-44-7 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 100% | 產(chǎn)品類(lèi)別: 抑制劑 |
貨號(hào): T27845 |
名稱(chēng) | Losigamone |
描述 | Losigamone (AO-33) is an agonist of GABA receptor and can be used in studies about the treatment of partial seizures. |
體內(nèi)活性 | Losigamone (AO-33) was tested in 52 healthy male volunteers in 4 placebo-controlled phase I studies. In the study 1 single dose of 100, 200, 300, 500, 700, and 1,000 mg losigamone was given as a fast-releasing capsule to 12 subjects. The pharmacokinetics of losigamone measured after administration of 100, 300, and 700 mg was linear. Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h. In study, 2,500 mg losigamone was given as a fast-release capsule for 6 days (t.i.d.) to 12 subjects. There was a small but statistically significant decrease for the AUC but no change in t1/2, Cmax, or tmax comparing single dose kinetics on days 1 and 8. There appeared to be no change in caffeine clearance on days 1 and 9. Study 2 was repeated in 20 volunteers with a film-coated tablet. Pharmacokinetic parameters appeared to be unaffected by this change in galenical formulation. In the study 4 daily doses of 400, 1,200, and 1,800 mg losigamone were given 28 days to 24 subjects. The kinetics of caffeine and antipyrine were compared on days 1 and 29. With the exception of t1/2 for antipyrine in the 400 mg group there was no statistically significant change in pharmacokinetic parameters. Generally, losigamone was well tolerated and no serious adverse side effects occurred. In some subjects, a reversible increase in transaminases was observed.[1] |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
關(guān)鍵字 | ADD137022 | Losigamone |
相關(guān)產(chǎn)品 | p-Hydroxybenzaldehyde | Penicillin G sodium salt | Valproic acid sodium salt | Valproic Acid | DL-Menthol | (-)-α-Pinene | Nikethamide | Riluzole | Chlorothymol | Piperazine citrate | Halothane | Gabapentin |
相關(guān)庫(kù) | 經(jīng)典已知活性庫(kù) | 已知活性化合物庫(kù) | 神經(jīng)遞質(zhì)受體化合物庫(kù) | 離子通道庫(kù) | 膜蛋白靶向化合物庫(kù) | 疼痛相關(guān)化合物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 589.8595萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠(chǎng),試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
VIP2年
|
浙江杰坤生物科技有限公司
|
2025-02-11 | |
詢(xún)價(jià) |
VIP5年
|
杭州固拓生物科技有限公司
|
2025-02-11 | |
¥85 |
VIP3年
|
紹興市均宇生物科技有限公司
|
2025-02-11 |